US regulator categorizes Aurobindo Pharma's American unit as official action indicated
The American drug regulator has classified a manufacturing plant belonging to Aurobindo Pharma's wholly owned step-down subsidiary as official action indicated. The inspection at the Seymour facility occurred from August 17 to August 21, 2026, according to a regulatory filing by the company.
Effective Not specified in the update
For professionals: Compliance officers and pharmaceutical auditors should review the company's subsequent disclosures for remediation updates. · Professionals should note that an official action indicated classification sits between voluntary action indicated and a warning letter.
Open for the full story →